Clinical Trial Update: A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b [NA]

View source ↗

Summary

ResMed's Phase 1b trial of expiratory pressure modulation in moderate to severe chronic obstructive pulmonary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Expiratory Pressure Modulation (device)

Snippet

Sponsor: ResMed | Conditions: Chronic Obstructive Pulmonary Disease | NA | Status: TERMINATED